Kadmon Holdings (NYSE:KDMN) is up 2.2% after hours following the acceptance of a late-breaking abstract of its trial of KD025 in chronic graft-versus-host disease for the 2020 Transplantation & Cellular Therapy Meetings.
That’s set for Feb. 19-23 in Orlando, Fla.
The expanded data set from the ROCKstar trial will include repsonse rate across key subgroups and initial safety data.
In November, Kadmon had said that KD025 met the primary endpoint at the interim analysis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.